US 12,077,554 B2
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
Adam Siddiqui-Jain, South Jordan, UT (US); Paul Flynn, Citrus Heights, CA (US); Yuji Fujiwara, Draper, UT (US); Shuji Masumoto, Toyonaka (JP); Hiroaki Tanaka, Toyonaka (JP); Hirotaka Kurebayashi, Minoh (JP); Takahiko Hashizuka, Matsubara (JP); and Yuka Arikawa, Minoh (JP)
Assigned to Sumitomo Pharma Oncology, Inc., Marlborough, MA (US)
Filed by Sumitomo Pharma Oncology, Inc., Marlborough, MA (US)
Filed on Nov. 10, 2022, as Appl. No. 18/054,435.
Application 18/054,435 is a continuation of application No. 17/225,836, filed on Apr. 8, 2021, granted, now 11,530,231.
Application 17/225,836 is a continuation of application No. 16/703,773, filed on Dec. 4, 2019, granted, now 11,034,710, issued on Jun. 15, 2021.
Claims priority of provisional application 62/775,303, filed on Dec. 4, 2018.
Prior Publication US 2023/0250116 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 9/00 (2006.01); C07F 9/6558 (2006.01)
CPC C07F 9/65586 (2013.01) [A61K 9/0053 (2013.01); A61P 35/00 (2018.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A method for treating a cancer in a mammal in need thereof, comprising administering to the mammal crystalline Form B of a compound having the following structure (I):

OG Complex Work Unit Chemistry
or a zwitterionic form thereof, in an amount of from about 1 mg to about 50 mg per day, wherein crystalline Form B is characterized by an x-ray powder diffraction pattern comprising at least three peaks at 2-theta angles selected from the group consisting of 4.8±0.2°, 10.8±0.2°, 13.7±0.2°, 14.9±0.2°, 20.0±0.2° and 24.6±0.2°.